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Nephropathia epidemica, caused by Puumala virus
(PUUV) infection, is a form of hemorrhagic fever with renal
syndrome of variable severity. Early prognostic markers for
the severity of renal failure have not been established. We
evaluated clinical and laboratory parameters of 15 consec-
utive patients with acute PUUV infection, which is endemic
in the Alb-Danube region, South Germany. Severe renal
failure (serum creatinine >620 µmol/L) was observed in
seven patients; four required hemodialysis treatment. Low
platelet count (<60 x 109/L), but not leukocyte count, C-
reactive protein, or other parameters obtained at the initial
evaluation, was significantly associated with subsequent
severe renal failure (p = 0.004). Maximum serum creatinine
was preceded by platelet count nadirs by a median of 4
days. Thrombocytopenia <60 x 10
9/L appears predictive of
a severe course of acute renal failure in nephropathia epi-
demica, with potential value for risk-adapted clinical dis-
ease management. 
W
orldwide, approximately 60,000–150,000 patients
per year are hospitalized with hantavirus infections
(1,2). Hantavirus spp. (Bunyaviridae family) are transmit-
ted to humans by inhalation of aerosolized excreta of per-
sistently infected rodents (3,4). Puumala virus (PUUV) is
a representative of this genus responsible for most cases of
hantavirus infections in northern Europe (1,5). The red
bank vole (Clethrionomys glareolus) is the natural host
reservoir of PUUV. Nephropathia epidemica attributable to
acute PUUV infection is a mild form of hemorrhagic fever
with renal syndrome (1,4–6). Endemic seasonal outbreaks
of PUUV infections are common in Scandinavia, but out-
breaks in central Europe are restricted to distinct regions,
e.g., in South Germany (2,4,7). 
Nephropathia epidemica is characterized by acute
fever, headache, nausea, vomiting, myalgia, abdominal
and loin pain, mild hepatitis and pancreatitis, and
interstitial nephritis with acute renal failure. Hemodialysis
is required in 10% to 30% of hospitalized patients with
acute PUUV infections (8). A complete recovery of renal
function is regularly achieved after several weeks (1,9).
Acute renal failure in nephropathia epidemica is frequently
accompanied by thrombocytopenia, elevated leukocyte
count, proteinuria, hematuria, and low serum calcium (9–
11), but early prognostic markers have not yet been
established to identify patients at high risk for a severe
course of acute renal impairment. We evaluated clinical
and laboratory parameters that could predict the severity of
acute renal failure suitable for risk-adapted disease
management in patients with nephropathia epidemica.
Patients and Methods 
From 1998 to 2001, all consecutive patients with
nephropathia epidemica and serologically confirmed han-
tavirus infection were studied. Patients were admitted by
physicians and regional hospitals to the nephrology divi-
sion of the University Hospital of Ulm, a center of
nephrology and infectious diseases in South Germany with
a patient base of 100 km (radius) on both sides of the River
Danube. Hemodialysis was started in patients with severe
symptoms of uremia (serum creatinine >620  µmol/L,
serum urea nitrogen >150 mg/dL, serum potassium >6.0
mmol/L, oliguria <500 mL/day, or progressive body
weight increase with edema). After discharge, a follow-up
examination of all patients was conducted in our outpatient
clinic. Blood pressure, leukocyte count, hemoglobin,
platelet count, prothrombin time, activated partial throm-
boplastin time, C-reactive protein, serum electrolytes, ala-
nine amino- transferase (ALT), serum protein, serum
creatinine, urea nitrogen, proteinuria, and microscopic
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Germany qualitative and quantitative (Addis count) urine analysis
were evaluated. Clinical and laboratory data obtained
before admission were also evaluated. The study protocol
was approved by the Ethics Committee, University of
Ulm, and written informed consent was obtained from all
patients. Studies were conducted in accordance with the
Declaration of Helsinki.
In all patients, acute hantavirus infection was serologi-
cally diagnosed by PUUV-specific immunoglobulin (Ig) G
enzyme immunoassay (EIA) (Progen, Heidelberg,
Germany). In addition, Hantaan virus (HTNV)-, PUUV-
and Dobrava virus (DOBV)-specific IgM and IgG antibod-
ies were detected by in-house monoclonal antibody–cap-
ture or µ-capture EIAs (Charité, Berlin), as previously
described (12); by immunofluorescence assays (IFA) using
HTNV-, PUUV-, and DOBV-infected Vero E6 cells; or by
an immunoblot (IB) using recombinant hantavirus anti-
gens (Mikrogen, Martinsried, Germany). In nine patients,
hantavirus serotyping was performed by chemilumines-
cence focus reduction neutralization assays (c-FRNTs), as
described recently (13).
Nonparametric tests were used for statistical analysis
(Fisher exact test, Mann-Whitney U test), and significance
was set at a level of p < 0.05. No adjustment for multiple
comparisons was made, and results were interpreted in an
exploratory manner. All statistical analyses were conduct-
ed with SPSS 8.0 software package (SPSS Inc., Chicago,
IL). If not indicated otherwise, data are given as median
values with range (minimum to maximum). 
Results 
Fifteen patients (mean age 37 ± 8 years; male:female
ratio12:3) with nephropathia epidemica were treated at the
University Hospital of Ulm from January 1998 to
December 2001 (Table 1). PUUV infections varied in
different years by number of patients and seasons with a
high incidence (Figure 1: November to December 1998: 2
patients; 1999 none; January to May 2000: 9 patients;
September to November 2001: 4 patients). All but one
patient lived on the north side of the River Danube. No
patient was working in agriculture, forestry, or other
professions considered at high risk for contact with
infected rodent excreta. Acute or chronic use of
nonsteroidal antiinflammatory drugs was denied. 
Patients were admitted to the hospital 5 days (range 2–
10 days) after acute onset of clinical symptoms, but the
first laboratory examination had already been performed 3
days (median, range 1–9 days) after onset of clinical
symptoms by general practitioners. Prominent clinical and
laboratory findings of acute nephropathia epidemica were
fever (100%), abdominal or loin pain (80%), fatigue
(67%), myalgia (60%), hepatitis (60%), headache (47%),
nausea (40%), and conjunctival bleeding (20%) (Table 1).
Dyspnea and pulmonary infiltrations were not observed on
x-ray images. Ultrasound examination showed intact
kidney forms in all patients. 
PUUV-reactive IgG and IgM antibodies were detected
in all patients (Table 2). EIA-positive results were
confirmed by at least one independent test (in-house EIA,
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Table 1. Characteristics of 15 patients with acute PUUV infection associated with mild or severe acute renal failure
a,b
 
  Mild acute renal failure  (n = 8)  Severe acute renal failure  (n = 7)  p value 
Age (y)  38 (25–53)  35 (22–53)  n.s.
c,d 
Sex (male:female r atio)  5:3  7:0  n.s.
e 
Fever (>38.5°C)  8  7  n.s.
e 
Abdominal or loin pain   7  5  n.s.
e 
Fatigue  4  6  n.s.
e 
Myalgia  5  4  n.s.
e 
Hepatitis (ALT  >20 U/mL)  4  5  n.s.
e 
Headache  4  3  n.s.
e 
Nausea/vomiting   1  5  0.041
e 
Conjunctival bleeding   1  2  n.s.
e 
Purpura  0  2  n.s.
e 
Highest C-reactive protein ( mg/L)  50 (27–112)  90 (7–122)  n.s.
d 
Lowest platelet count (x 10
9/L)
b  113 (26–250)  34 (18–122)  0.016
d 
Highest leukocyte count (x 10
9/L)  9.9 (8.0–15.3)  15.1 (12.0–22.7)  0.029
d 
Lowest serum calcium (mmol/L)   2.22 (1.85–2.27)  2.02 (1.98–2.21)  0.029
d 
Hematuria (cells/min)  10.2 (2.6–27)  76.4 (21.2–129.0)  0.009
d 
Leukocyturia (cells/min)   16.2 (10.4–22)  41.0 (17.5–191.0)  0.0017
d 
Proteinuria (>1.5 g/day)  2  4  n.s.
e 
Tubular cell casts   1  5  0.001
e 
aPUUV, Puumala virus; mild and severe acute renal failure was defined as serum creatinine  £620 µmol/L and >620 µmol/L, respectively; ALT, alanine 
aminotransferase .  
bOf all parameters, only thrombocytopenia predicted subsequent severe renal failure. Medians (range) and actual number of patients are given.   
cn.s., not significant.  
dMann-Whitney U test.   
eFisher exact test.  IFA, IB). During the acute phase of PUUV infection, cross-
reactive neutralizing antibodies to other hantavirus
serotypes (HTNV, Tula virus) were detected in two patients
(c-FRNT), but PUUV infection was confirmed in the
convalescent-phase infection by high endpoint titers for
PUUV antibodies compared to other hantavirus serotypes.
Because of the limited quantity of serum specimens, the
complete array of virologic tests was not performed in all
samples, but available serologic data demonstrated acute
PUUV infections in all patients (Table 2). 
In all patients, a combination of low platelet count
(<150 x 109/L), elevated serum creatinine (>150 µmol/L),
or elevated C-reactive protein (>10 mg/L) was detected. In
seven patients (47%), severe acute renal impairment with
a serum creatinine >620 µmol/L developed; four (27%) of
these patients required hemodialysis as an acute
intervention for 3 days (range 2–9 days) because of
symptoms of uremia. During hospital stay, polyuria (>3
L/day) was present in only three patients (20%), and no
patient became anuric (<500 mL/day). Serum protein was
>60 g/L in all patients, plasma coagulation parameters
were not altered, and mild bleeding signs (subconjunctival
bleeding, petechiae) were present in only three patients
with a platelet count <60 x 109/L. Patients remained in the
hospital for 10 days (range 5–19 days), and follow-up
examination was conducted at our outpatient clinic for 5
months (range 0.2–12.5 months).
We found that lower platelet count, higher leukocyte
count, the presence of tubular cell casts in urine,
quantitative hematuria and leukocyturia (Addis count), and
nausea were significantly associated with severe acute
renal failure (serum creatinine >620 µmol/L) (Table 1). In
contrast, age, sex, blood pressure, fever, abdominal or loin
pain, myalgia, headaches, fatigue, bleeding signs,
hemoglobin, prothrombin time, activated partial
thromboplastin time, C-reactive protein, sodium,
potassium, ALT, serum protein, and proteinuria were not
associated with serum creatinine >620 µmol/L (Table 1). 
The platelet count nadir was observed 4 days (range 1–
6 days) after the acute onset of clinical symptoms. Seven
days after initial symptoms (range 3–12 days), platelet
counts had already returned to normal in all patients, with
values  >150 x 109/L (Figure 2). Maximum serum
1422 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 8, August 2004
RESEARCH
Figure 1. Residence of 15 study patients with hantavirus infection
and nephropathia epidemica, according to year of diagnosis (X,
November–December 1998; black circle, January–May 2000;
black square, September–November 2001). Note the River
Danube as a potential natural barrier of Puumala virus hantavirus
infection. Shaded circle indicates Ulm city.
Table 2. Virologic results of 15 patients with acute PUUV infection
a 
Patient 
IgG-EIA 
(Progen) index   IgG titers  IgM titers  c-FRNT titers 
  PUUV  PUUV  HTNV  DOBV  PUUV  PUUV  HTNV  DOBV  SEOV  TULV 
1  9  6,400  Neg  Neg  3,200  640  <40  160  <40  160 
2  2.1  2,560  640  –  2,560  –  –  –  –  – 
3  2.2  6,400  400  400  1,600  2,560  <40  <40  <40  40 
4  3.3  51,200  6,400  400  12,800  640  160  40  <40  160 
5  3.8  51,200  3,200  Neg  Pos
b  2,560  160  40  <40  40 
6  3.1  6,400  800  Neg  6,400  2,560  640  40  <40  160 
7  3.1  12,800  800  Neg  1,280  640  <40  <40  –  40 
8  4.3  12,800  3,200  800  3,200  2,560  160  40  <40  160 
9  1.8  Pos
c  –  –  Pos
c  –  –  –  –  – 
10  2.9  12,800  3,200  3,200  400  2,560  160  40  <40  160 
11  7.1  12,800  1,600  400  1,600  –  –  –  –  – 
12  2.9  Pos
c  –  –  Pos
c  –  –  –  –  – 
13  4.9  51,200  400  Neg  3,200  –  –  –  –   
14  2.5  Pos
c  –  –  Pos
c  –  –  –  –  – 
15  3.3  12,800  1,600  400  1,600  2,560  40  <40  40  40 
aPUUV, Puumala virus; Ig, immunoglobulin; EIA, enzyme immunoassay; c-FRNT, chemiluminescence focus reduction neutralization assays; HTNV, 
Hantaan virus; DOBV, Dobrava virus; SEOV, Seoul virus; TULV, Tula virus; –, not available.  
bIgM-EIA (Progen, Heidelberg, Germany ). 
cImmunoblot (Mikrogene, Martinsried, Germany).  creatinine values were observed 7 days (range 3–14 days)
after onset of disease, and renal function returned to
normal within 14 days (range 7–38 days) after onset of
symptoms, as defined by serum creatinine <150 µmol/L. 
In patients with severe renal failure, platelet count
nadirs preceded maximum serum creatinine values by 4
days (range 2–10 days). In patients with a mild or severe
course of acute renal failure, the platelet count was differ-
ent at initial evaluation (p = 0.04), but serum creatinine
values at initial evaluation did not differ (p = 0.15). We
analyzed the potential prognostic value of low (<60 x
109/L) and moderately decreased (>60 x 109/L) platelet
count for the severity of subsequent renal failure. This
value represented the median of all patients at first evalua-
tion, which generated two equally sized patient cohorts.
The time interval between initial clinical symptoms and
first laboratory evaluation did not differ in the two groups
(2 days, range 0–6 days). A platelet count of <60 x 109/L
preceded severe renal failure in six of seven patients, and
all patients with hemodialysis had a platelet count <60 x
109/L in the early phases of infection. Acute severe renal
impairment (sensitivity 0.86, specificity 0.88, positive
predictive value 0.86) developed in one of eight patients
with a platelet count >60 x 109/L. The initial serum
creatinine value was not different in the two groups (p =
0.54, Mann-Whitney U test), but the maximum value was
significantly higher in patients with a platelet count of <60
x 109/L during the early phase of infection (Figure 3A).
Although associated with a severe course of nephropathia
epidemica (Table 1), an increased leukocyte count at first
examination was not predictive of the severity of
subsequent renal failure (Figure 3B).
Discussion 
Early prognostic parameters for the course of renal
impairment might be beneficial for risk-adapted disease
management of nephropathia epidemica, but they have not
been established to date (1,14). Thrombocytopenia is a
well-known transient symptom of this condition (15), and
we found that severe thrombocytopenia (<60 x 109/L) was
a prognostic parameter predictive for consecutive severe
acute renal failure (serum creatinine >620 µmol/L). 
In Germany, the hantavirus seroprevalence in humans
is 1%–2%, but higher seroprevalences are found in dis-
ease-endemic regions, such as the Alb-Danube Region,
South Germany (16). Most of our patients might have
acquired PUUV infection during leisure activities, as occu-
pations were not found to be risk factors in this study.
Fluctuations of infected rodent populations may be respon-
sible for the seasonal and endemic outbreaks of PUUV
infections (4,6–18). Most patients with nephropathia epi-
demica resided to the north of the River Danube (Figure
1), which raises the possibility that the river acts as a geo-
graphic barrier for the migration of PUUV-infected rodent
populations. However, direct evidence for this assumption
was not provided in this study. 
The diagnosis of an acute PUUV infection is estab-
lished by detecting PUUV-specific IgM antibodies (19).
Cross-reactive neutralizing antibodies to closely related
hantavirus serotypes are common in the early but not in the
convalescent phase of infection (20,21), as observed in two
patients. In all patients, acute PUUV infection was proven
by the different serologic tests, which were equally able to
discriminate various hantavirus serotypes (Table 2). 
Infections of endothelial and tubular cells, in conjunc-
tion with various immunologic mechanisms, are responsi-
ble for acute renal failure and thrombocytopenia in
nephropathia epidemica. The maturation of hantavirus-
infected dendritic cells may efficiently stimulate a pro-
inflammatory immune response of specific T cells (22). β3
integrins are adhesive receptors on platelets and endothe-
lial cells and may contribute to capillary leak and platelet
activation in PUUV infection (3,23,24). Endothelial cell
damage, circulating immune complexes, complement acti-
vation, T-cell activation, and cytokine response with high
levels of tumor necrosis factor-α and interleukin-6 might
cause acute renal failure and peripheral consumption of
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Figure 2. Course of serum creatinine (A) and platelet count (B) in
patients with mild (diamond, serum creatinine <620 µmol/L, n = 8)
or severe acute renal failure (black square, serum creatinine >620
µmol/L, n = 7). Mean values and SD are shown. *Denotes evalua-
tion at end of followup (median, 5 months).platelets (9,25,26). Similar to PUUV infections, severe
thrombocytopenia may predict severe organ failure in
other infectious diseases, including Rocky Mountain spot-
ted fever (27). 
In our patients, acute PUUV infection was a highly
dynamic process, characterized by a short transient throm-
bocytopenia followed by mild-to-severe acute renal failure.
We found statistical evidence that severe thrombocytopenia
(<60 x 109/L) is a significant early prognostic parameter for
subsequent severe acute renal failure (serum creatinine
>620 µmol/L). In other studies, thrombocytopenia was not
identified as a predictive marker for severe acute renal fail-
ure (9,28); in these studies, laboratory data before hospital
admission were not reported (9,28). These parameters were
included to evaluate the earliest phase of infection.
Leukocyte count was elevated in patients with a severe
course of renal failure but was not predictive at first exam-
ination (Figure 3B). Similarly, quantitative hematuria,
quantitative leukocyturia, and tubular cell casts obtained 1
day (range 0–12 days) after admission to hospital were
associated with, but not predictive for, severe renal failure. 
A specific therapy for nephropathia epidemica is not
generally applicable, but a symptomatic therapy including
hemodialysis may be individually required. If the platelet
count is <60 x 109/L in the early phase of infection, acute
renal failure with serum creatinine >620  µmol/L is
impending, and a tight control of clinical and laboratory
parameters, including hospitalization, is mandatory. A
platelet count >60 x 109/L in the early phase of infection is
predictive for mild renal failure, and outpatient treatment
might be possible in absence of uremia, anuria, pulmonary
symptoms, or other signs of severe infection. If a patient’s
platelet count has not dropped below 60 x 109/Lbefore day
6 after initial symptoms, the clinician may feel relatively
comfortable predicting that severe renal failure will not
occur. Later phases of infection are characterized by
increased serum creatinine values but normalizing platelet
counts (Figure 2). Early discharge from hospital may be
justified in all patients at low risk for consecutive severe
acute renal failure and in all patients with ongoing recon-
stitution of renal function. Thus, platelet counts obtained
during the early phase of infection are suggested as a
promising parameter for a risk-adapted, cost-effective dis-
ease management. 
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